2025-09-11: DEUSG Virtual

Opening

2 min

Shane / Alejandro

Welcome & Notification of Recording

Consolidation of unit or product usage versus unit of presentation

10 min

Nicki

• Update of any feedback to UKs proposal 

• Next Steps (Draft BN)

• A Briefing Note has been drafted, and is attached to this page for group review. It will be issued through the usual publication route in due course.

• There is opportunity for further review and clean up of remaining 'units of product usage' and group could explore this as a follow up step to the current briefing note.

Strength representation for gas medicinal products

10 min

Linda Bird

As part of developing the Canadian Medicines Terminology, we need to understand the editorial rules used by international clinical drugs, to ensure that we don’t create duplicate extension concepts. With this in mind, could you please help to clarify the strength rules for the gas products. On the one hand, the Editorial Guide (under ‘Product strength numerator values’ on https://snomed.atlassian.net/wiki/display/DOCEG/Clinical+drug ), indicates that strengths are normalised when a strength value is less than one. However (as per the image below), there are several gas products with a strength < 1. Most of the gas products seem to use a strength units of mL/mL … however, I can’t find this documented anywhere.

My question- Which of the drug products below, with a gas state of matter, have a correctly defined strength? Is it the one with a strength of “900 nanogram/1 milliliter”, or is it the eight that have a strength value less than one (e.g. “0.09”) but with a units of mL/mL? And will the incorrect ones be fixed at some stage? It would be very helpful to have a rule that we can follow for these.

• 11 Concepts identified (10 gas, 1 oral capsule). SI will review, likely no Briefing Note etc. required as no change in Editorial Policy here, content clean up to adhere to current rule.

Platform Migration – Updates

10 min

Alejandro / Krista

Overview of new collaboration platforms:

• SNOMED Spaces: New homepage for DEUSG and meeting notes etc. Will become read only for group members.

• SNOMED Forums: New home for all discussions going forward. Existing topics have been transferred over. This will be the main route of communication with group members going forward (notification of upcoming meetings etc.).

Less granular clinical drug

10 min

Shane

• Does anyone have existing modelling to share?

• What does this look like to countries? (start with a current Clinical Drug)

• Group members to share any existing modelling in use to Shane/Alejandro or to info@snomed.org FAO of Drug Content Team.

• Guillermo has been analysing a list of 600 examples and will be ready to share with the group soon for discussion.

Updates from countries & Topic proposals for October meetings

10 min

All

• Guillermo: Multi-component clinical drugs

• Linda: Modelling of transformed dose forms.

• Group members to continue to share topics/discussion areas ahead of October.

AOB

10 min

All